Loading...
Contraindications to intravenous rtPA for acute stroke: A critical reappraisal
Only 1%–5% of patients with acute ischemic stroke presenting within 3 hours of symptoms receive IV recombinant tissue plasminogen activator (rtPA)—the only effective treatment available. The administration of rtPA is limited by extensive exclusion criteria, many of which are not based on evidence, b...
Saved in:
| Published in: | Neurol Clin Pract |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Academy of Neurology
2013
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5798502/ https://ncbi.nlm.nih.gov/pubmed/29473642 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0b013e318296f0a9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|